EPS for Ascendis Pharma A/S (ASND) Expected At $-0.93

May 21, 2018 - By wolcottdaily

Analysts expect Ascendis Pharma A/S (NASDAQ:ASND) to report $-0.93 EPS on May, 22.They anticipate $0.10 EPS change or 12.05 % from last quarter’s $-0.83 EPS. After having $-1.08 EPS previously, Ascendis Pharma A/S’s analysts see -13.89 % EPS growth. The stock decreased 0.94% or $0.63 during the last trading session, reaching $66.29. About 66,015 shares traded. Ascendis Pharma A/S (NASDAQ:ASND) has risen 130.09% since May 21, 2017 and is uptrending. It has outperformed by 118.54% the S&P500.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Coverage

Among 4 analysts covering Ascendis Pharma (NASDAQ:ASND), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ascendis Pharma had 12 analyst reports since January 3, 2018 according to SRatingsIntel. The company was maintained on Monday, May 14 by J.P. Morgan. The rating was maintained by Credit Suisse on Tuesday, March 20 with “Outperform”. Wedbush maintained Ascendis Pharma A/S (NASDAQ:ASND) rating on Tuesday, May 15. Wedbush has “Buy” rating and $7600 target. The stock has “Buy” rating by Wedbush on Friday, January 5. Wedbush maintained it with “Buy” rating and $62.0 target in Tuesday, February 6 report. Credit Suisse maintained Ascendis Pharma A/S (NASDAQ:ASND) on Thursday, February 22 with “Buy” rating. The stock has “Buy” rating by Bank of America on Thursday, January 25. The firm earned “Buy” rating on Monday, March 19 by Wedbush. The stock has “Buy” rating by J.P. Morgan on Wednesday, January 17. The stock has “Buy” rating by Wedbush on Monday, February 26.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. The company has market cap of $2.75 billion. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. It currently has negative earnings. The firm is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

More important recent Ascendis Pharma A/S (NASDAQ:ASND) news were published by: Nasdaq.com which released: “Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNP” on May 08, 2018, also Benzinga.com published article titled: “Top Ideas From The 2018 Sohn Conference: Box, Bitcoin, Facebook, Palo Alto And More”, Globenewswire.com published: “Ascendis Pharma A/S Announces Upcoming Investor Presentations” on April 25, 2018. More interesting news about Ascendis Pharma A/S (NASDAQ:ASND) was released by: Nasdaq.com and their article: “Ascendis Pharma A/S Announces First Quarter 2018 Financial Results and Business Update Conference Call on May 30” with publication date: May 10, 2018.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.